Journal of Clinical Pharmacy and Therapeutics · 2013 · 18 citations · 19 references
MedicineHematologyImmunologyCancer ImmunologyChemotherapyImmunotherapyCancer ImmunotherapyChemotherapy In Hematologic MalignanciesCytokine-mediated PathologyImmune-related Adverse EventsInterstitial Lung DiseasePulmonary Toxicity ManagementAnti-cd20 Antibody TherapyAnti-cd20 TherapyChemotherapy-induced Pulmonary ToxicityLymphoma ChemotherapyRituximab-based TherapySerious Adverse Drug ReactionsSerious Adverse Events
WHAT IS KNOWN AND OBJECTIVE: Rituximab, an anti-CD20 monoclonal antibody, is widely used with good response for the treatment of B-cell lymphoma and various refractory autoimmune diseases. Although rituximab is effective, rare but serious pulmonary adverse reactions have been reported. We report on a case of rituximab-induced life-threatening interstitial lung disease in a patient with diffuse large B-cell lymphoma (DLBCL), and describe the patient's serum cytokine profile during anti-TNF-α treatment. CASE SUMMARY: A 71-year-old woman diagnosed with DLBCL was treated with three cycles of rituximab-containing chemotherapy. She developed a fatal respiratory failure, which was eventually diagnosed as rituximab-induced interstitial lung disease (R-ILD). The R-ILD in this patient did not respond to intensive steroid treatment, or to enternacept, an anti-TNF therapy. During therapy, we observed that the serum level of IL-6 was much higher at the beginning of treatment than was usual for other DLBCL patients. Levels of IL-6 and TNF-α also increased during the course of the clinical exacerbation. We undertook a literature search and reviewed similar cases of R-ILD. WHAT IS NEW AND CONCLUSION: Although rituximab is generally effective and safe, caution is required for high-risk patients, as in our case, and as reported in several other cases in the literature. Cytokine analysis may help in identifying patients at high risk of R-ILD. Better intensive therapeutic approaches other than steroids are required even during the early stages of the complication.
19
U. Winkler, Mark A. Jensen, Oliver Manzke et al. · Blood · 1999 · 658 citations
Christian Buske, Eva Hoster, Martin Dreyling et al. · Leukemia · 2008 · 155 citations